For instance, in rheumatoid arthritis and psoriatic arthritis, the combination of biologics targeting different inflammatory pathways (e.g., TNF inhibitors with IL-17 or IL-6 blockers) has shown clinical potential in refractory cases, despite limited safety data (15). Here, TNF is linked to psoriatic arthritis.